Pfizer and XtalPi Broaden Partnership to Accelerate AI-Powered Drug Development and Materials Science Research
XtalPi, a leading technology company, has announced an expansion of its research collaboration with Pfizer to develop a next-generation molecular modeling platform for drug discovery. The goal of this initiative is to improve the accuracy of advanced physics-based...
Rajkummar Rao appointed as the Brand Ambassador for Nimulid Strong by Mankind Pharma
Mankind Pharma, India's fourth-largest pharmaceutical company, has appointed Rajkummar Rao as the brand ambassador for its flagship product, Nimulid Strong Pain Relief Gel & Spray. This move aims to strengthen the company's position in the topical pain relief segment....
US FDA issues single Form 483 observation to NATCO Pharma’s Hyderabad plant following audit.
NATCO Pharma, a leading pharmaceutical company based in Hyderabad, India, has received a positive outcome from a recent US Food and Drug Administration (US FDA) audit. The company's plant, located in Hyderabad, was inspected by the US FDA, and the audit resulted in...
Alexey Cherchago shares insights on Glenmark’s emphasis on innovation and technological advancements in the rapidly changing pharmaceutical industry.
Alexey Cherchago, a leading expert in the pharmaceutical industry, recently discussed Glenmark's focus on innovation and technology in the evolving pharmaceutical market. Glenmark, a global pharmaceutical company, has been at the forefront of innovation, leveraging...
Lupin Introduces Prucalopride Tablets to the US Market – BW Healthcare
Lupin, a global pharmaceutical company, has announced the launch of Prucalopride tablets in the United States. Prucalopride is a serotonin receptor agonist used to treat chronic idiopathic constipation (CIC) in adults. The medication works by increasing the movement...
Biocon Partners with NCSM to Enhance Accessibility of Affordable Biosimilars
Biocon Biologics Ltd, a global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Programme (PAP) aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in...
My life as a fit father of four was turned upside down after receiving the Pfizer Covid vaccine, sparking a devastating chain of events that has cost me £100,000 in a desperate search for a cure.
Dean Valentine, a 59-year-old grandfather from Essex, claims that his life was turned upside down after receiving the Pfizer Covid vaccine in December 2021. Prior to the vaccine, Valentine was a healthy and active individual who enjoyed golfing, holidays, and spending...
Pfizer obtains worldwide licensing rights, excluding China, for 3SBio’s innovative cancer treatment SSGJ-707, a dual-target therapy.
Pfizer has secured global licensing rights, excluding China, for 3SBio's dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a...
Fake versions of Sun Pharma’s cholesterol-lowering medications confiscated in Hyderabad
In a significant crackdown on counterfeit pharmaceuticals, the Telangana Drugs Control Administration (DCA) has seized fake versions of heart medications Rosuvas F 20 and Rosuvas F 10 in Hyderabad's Koti area. The counterfeit cholesterol-lowering drugs, labeled under...
Authorities in Hyderabad confiscate fake Sun Pharma cholesterol medication valued at Rs 3 lakhs
In a significant crackdown on counterfeit medicines, a large consignment of fake Sun Pharma cholesterol-lowering drugs worth approximately Rs 3 lakhs was seized in Hyderabad. The seizure is a result of a coordinated effort between law enforcement agencies and...
Sun Pharmaceutical Industries Appoints Kirti Ganorkar as MD Amidst Top-Level Restructuring – MSN
Sun Pharmaceutical Industries, one of India's largest pharmaceutical companies, has announced a significant leadership overhaul with the appointment of Kirti Ganorkar as its new Managing Director. This move is part of a broader effort to revamp the company's...
Sun Pharmaceutical Industries plans to allocate $100 million for the commercialisation of its specialty products during the current fiscal year.
Sun Pharmaceutical Industries, a leading drug manufacturer, has announced plans to invest $100 million in the current fiscal year to commercialize innovative products, with a focus on strengthening its specialty business. The investment will be used to launch two new...
Next-gen leaders are revitalizing India’s pharmaceutical landscape as family-run drug empires successfully navigate leadership transitions.
India's largest pharmaceutical companies, such as Sun Pharmaceutical Industries Ltd and Torrent Pharmaceuticals Ltd, are preparing the next generation of their promoter families to take over the reins. Recently, Torrent Pharma announced the appointment of Aman Mehta,...
Sun Pharmaceutical Industries receives US FDA approval for cutting-edge skin treatment device.
Sun Pharmaceutical Industries has received approval from the US Food and Drug Administration (FDA) for a new medical device designed to treat actinic keratoses (AK), a skin condition caused by prolonged sun exposure. AK is characterized by the appearance of red, rough...
Nomura Warns: Trump’s Drug Pricing Order Could Have Significant Impact on Sun Pharma
The pharmaceutical sector is facing uncertainty after US President Donald Trump signed an executive order on May 12, requiring US drug companies to align their prices with those in other developed countries. This move could have a significant negative impact on the...
Sun Pharmaceuticals unveils its first-ever corporate brand initiative in the Indian market
Sun Pharmaceutical Industries (Sun Pharma) has launched a corporate brand campaign titled "Touching 1,000 Lives Every Minute" to highlight its role in supporting patients, caregivers, doctors, pharmacists, and communities. The campaign showcases the company's...
Access to the Request Has Been Denied
It appears that you have encountered an error while trying to access the website www.tipranks.com. The error message indicates that your request was blocked by Link11 Web Application Security, which is a security system designed to protect websites from malicious...
US FDA issues single Form 483 observation to NATCO Pharma’s Hyderabad plant following audit.
NATCO Pharma, a leading pharmaceutical company based in Hyderabad, India, has received a positive outcome from a recent US Food and Drug Administration (US FDA) audit. The company's plant, located in Hyderabad, was inspected by the US FDA, and the audit resulted in...
Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company's quarterly...
Divis Laboratories signs long-term manufacturing and supply pact with international pharmaceutical company.
Divis Laboratories has secured a long-term manufacturing and supply agreement with a global pharmaceutical company. Under the terms of the agreement, Divis will manufacture and supply advanced intermediates to the pharma company, with the details of the commercial...
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic...
SMA patients welcome Natco’s development of a generic drug, calling on the government to ensure timely access to it.
The article reports on the recent development of a generic drug by Natco Pharmaceuticals, a leading Indian pharmaceutical company, which is expected to benefit patients suffering from Spinal Muscular Atrophy (SMA). SMA is a genetic disorder that affects the muscles,...
Patents for Pharmaceuticals: Balancing Exclusive Rights with Public Welfare
The Indian court, Justice Mini Pushkarna, recently ruled against granting an injunction in favor of Roche, a pharmaceutical company, in a landmark case involving the patent dispute over the drug Risdiplam, used to treat Spinal Muscular Atrophy (SMA). The court's...
Natco Pharma’s Executive Vice President of Technology Transfer, Intellectual Property Rights and Regulatory Affairs, Dr Ramesh Dandala, retires.
A Senior Executive at Natco Pharma Retires Natco Pharma, a leading Indian pharmaceutical company, has announced the superannuation of Dr. Ramesh Dandala, the Executive Vice President of Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API). Dr....
Pfizer and XtalPi Broaden Partnership to Accelerate AI-Powered Drug Development and Materials Science Research
XtalPi, a leading technology company, has announced an expansion of its research collaboration with Pfizer to develop a next-generation molecular modeling platform for drug discovery. The goal of this initiative is to improve the accuracy of advanced physics-based...
Rajkummar Rao appointed as the Brand Ambassador for Nimulid Strong by Mankind Pharma
Mankind Pharma, India's fourth-largest pharmaceutical company, has appointed Rajkummar Rao as the brand ambassador for its flagship product, Nimulid Strong Pain Relief Gel & Spray. This move aims to strengthen the company's position in the topical pain relief segment....
US FDA issues single Form 483 observation to NATCO Pharma’s Hyderabad plant following audit.
NATCO Pharma, a leading pharmaceutical company based in Hyderabad, India, has received a positive outcome from a recent US Food and Drug Administration (US FDA) audit. The company's plant, located in Hyderabad, was inspected by the US FDA, and the audit resulted in...
Alexey Cherchago shares insights on Glenmark’s emphasis on innovation and technological advancements in the rapidly changing pharmaceutical industry.
Alexey Cherchago, a leading expert in the pharmaceutical industry, recently discussed Glenmark's focus on innovation and technology in the evolving pharmaceutical market. Glenmark, a global pharmaceutical company, has been at the forefront of innovation, leveraging...
Lupin Introduces Prucalopride Tablets to the US Market – BW Healthcare
Lupin, a global pharmaceutical company, has announced the launch of Prucalopride tablets in the United States. Prucalopride is a serotonin receptor agonist used to treat chronic idiopathic constipation (CIC) in adults. The medication works by increasing the movement...
Biocon Partners with NCSM to Enhance Accessibility of Affordable Biosimilars
Biocon Biologics Ltd, a global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Programme (PAP) aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in...
My life as a fit father of four was turned upside down after receiving the Pfizer Covid vaccine, sparking a devastating chain of events that has cost me £100,000 in a desperate search for a cure.
Dean Valentine, a 59-year-old grandfather from Essex, claims that his life was turned upside down after receiving the Pfizer Covid vaccine in December 2021. Prior to the vaccine, Valentine was a healthy and active individual who enjoyed golfing, holidays, and spending...
Pfizer obtains worldwide licensing rights, excluding China, for 3SBio’s innovative cancer treatment SSGJ-707, a dual-target therapy.
Pfizer has secured global licensing rights, excluding China, for 3SBio's dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a...
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla's Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility...
Amit Patel has been promoted to lead Consumer Marketing Excellence as its new Head.
Amit Patel has been promoted to Head of Consumer Marketing Excellence at Cipla India, a leading pharmaceutical company. In his new role, Patel will be responsible for driving consumer marketing across various therapeutic areas, with a focus on building patient-centric...
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth...
Cipla Limited and its division EMEU, have been honoured at the prestigious Healthcare Asia Pharma Awards 2025.
Cipla EMEU and Cipla Limited have been recognized at the Healthcare Asia Pharma Awards 2025 for their innovative initiatives. Cipla EMEU received the ESG Program of the Year - India award for its Ahead & Apart campaign, which promotes sustainable practices in the...
Cipla to Report Q4 FY 2025 Earnings on May 13, Dividend Payment Possible
Pharmaceutical company Cipla has announced the date for its earnings release for the fourth quarter and full year ended March 31, 2025. The company's Board of Directors is scheduled to meet on Tuesday, May 13, 2025, to consider and approve the standalone and...
A sudden surge in demand for Doxorubicin may send market momentum soaring, with influential companies like Merck & Co., Lupin, and Cipla playing a pivotal role.
The latest survey on the Doxorubicin market has been conducted to provide a comprehensive analysis of the market's performance, competitive environment, and market size. The report covers the period from 2019 to 2024 and provides a forecast till 2031. The market size...
Cipla Lacrosse up a massive partnership with Formosa, securing a sweeping deal spanning 11 countries for their clobetasol offerings.
Cipla, a leading global pharmaceutical company, has signed an exclusive licensing agreement to expand its ophthalmology portfolio and global offerings. The agreement involves the acquisition of Formosa Pharmaceuticals' US FDA-approved clobetasol propionate 0.05%...
Eli Lilly expands its global footprint by introducing Mounjaro, a groundbreaking weight management medication, to the Indian market.
Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country's first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the blood and...
AI has the potential to revolutionize India’s healthcare industry, according to Apollo’s Shobhana Kamineni.
Shobhana Kamineni, the executive chairperson of Apollo Hospitals, believes that artificial intelligence (AI) has the potential to transform India's healthcare sector more deeply than other industries. According to Kamineni, India faces significant challenges in terms...
At 92, a resilient entrepreneur still commutes to the office every day, spearheading India’s largest healthcare network as the founder of [company name], a feat achieved by the indefatigable [his name].
Dr. Prathap C. Reddy is a 92-year-old man who still goes to office every day, six days a week, and is the guiding force behind Apollo Hospitals, India's largest healthcare network. He founded Apollo Hospitals in 1983, which was India's first corporate hospital,...
Larsen & Toubro to construct hospitals valued at Rs 24 billion for Apollo, as reported by Construction World.
Larsen & Toubro (L&T), a leading Indian multinational conglomerate, has bagged a significant contract from Apollo Hospitals to build multiple hospitals across the country. The total value of the contract is estimated to be around Rs 24 billion (approximately $330...
Apollo Cradle and Children’s Hospital, headquartered in Hyderabad, is poised for substantial growth with plans to launch 7-8 new facilities over the next five years. – TRIPURA STAR NEWS
Apollo Cradle and Children's Hospital, a prominent healthcare provider, has announced plans for significant expansion in the next five years. Headquartered in Hyderabad, the hospital aims to set up 7-8 new centers across the country, catering to the growing demand for...
Apollo Hospitals Introduces ‘Fleet of Hope’ on World Emergency Medicine Day to Promote Awareness About 1066 Emergency Services
On World Emergency Medicine Day, Apollo Hospitals launched the "Fleet of Hope" initiative to raise awareness about its 1066 emergency services. The campaign aims to educate the public about the importance of emergency medical services and the role they play in saving...
Apollo Hospitals Sees Significant Increase in International Research Recognition
The Apollo Hospitals Group has made significant contributions to global healthcare research, as highlighted in a recent publication in the National Board of Examination Journal of Medical Sciences. The study, "Evaluating a Decade of Research Excellence: A Bibliometric...
Apollo introduces a revolutionary non-surgical treatment for piles, transforming patient care – Healthcare Radius
Apollo Hospitals has introduced a new non-surgical procedure to treat piles, also known as hemorrhoids. This innovative treatment offers a pain-free and minimally invasive solution for patients suffering from this common condition. Piles are swollen blood vessels in...
Meet the 92-year-old entrepreneur who has amassed a staggering net worth of Rs 27,500 crore, owning an impressive 71 hospitals and 5000 pharmacies, and still reports to his office every day.
Meet Dr. Prathap C. Reddy, a 92-year-old cardiologist and founder of the Apollo Hospitals chain, a multinational hospital network headquartered in Chennai, India. With a net worth of approximately Rs 27,500 crore, Dr. Reddy is a remarkable individual who has dedicated...
Pfizer and XtalPi Broaden Partnership to Accelerate AI-Powered Drug Development and Materials Science Research
XtalPi, a leading technology company, has announced an expansion of its research collaboration with Pfizer to develop a next-generation molecular modeling platform for drug discovery. The goal of this initiative is to improve the accuracy of advanced physics-based...
My life as a fit father of four was turned upside down after receiving the Pfizer Covid vaccine, sparking a devastating chain of events that has cost me £100,000 in a desperate search for a cure.
Dean Valentine, a 59-year-old grandfather from Essex, claims that his life was turned upside down after receiving the Pfizer Covid vaccine in December 2021. Prior to the vaccine, Valentine was a healthy and active individual who enjoyed golfing, holidays, and spending...
Pfizer obtains worldwide licensing rights, excluding China, for 3SBio’s innovative cancer treatment SSGJ-707, a dual-target therapy.
Pfizer has secured global licensing rights, excluding China, for 3SBio's dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a...
Ireland lags behind in pharmaceutical research and development as highlighted by Pfizer’s recent announcement
Pharmaceutical companies, led by Pfizer's CEO Albert Bourla, met with the Trump administration to discuss the implementation of an executive order signed by President Trump on May 12. The order requires drug companies to align their US prices with the lowest price of...
Pfizer’s Talzenna faces setback as FDA advisory panel votes against expanded approval for prostate cancer treatment amidst growing role of AI in clinical trial diversity.
The FDA Advisory Panel has rejected Pfizer's proposal to expand the use of Talzenna, a PARP inhibitor, for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The panel's decision was based on the lack of sufficient evidence to support the...
Pfizer acquires international rights, excluding China, for 3SBio’s innovative cancer treatment SSGJ-707, a dual-target therapy.
Pfizer has recently secured the global rights outside of China for 3SBio's dual-target cancer therapy, SSGJ-707. This deal marks a significant collaboration between the two companies, with Pfizer gaining exclusive rights to develop, manufacture, and commercialize...
Pfizer’s attempt to broaden Talzenna’s indications is rejected by FDA panel as artificial intelligence is investigated for its potential to increase diversity in clinical trials.
A US Food and Drug Administration (FDA) advisory panel has rejected Pfizer's bid to expand the use of its breast cancer drug, Talzenna (talazoparib). The panel voted against approving the medication for use in patients with a type of breast cancer known as hormone...
Pfizer’s Talzenna Fails to Win FDA Panel Approval for Expanded Use in Prostate Cancer Treatment Amid Growing Focus on AI-Driven Clinical Trial Inclusion.
A US Food and Drug Administration (FDA) advisory panel has rejected Pfizer's bid to expand the use of its drug Talzenna (talazoparib) to treat metastatic prostate cancer. The panel's decision was based on the results of a clinical trial that failed to show a...
Fortis Hospital, Manesar Achieves Breakthrough in Treating 38-Year-Old Stage 4 Head and Neck Cancer Patient with Innovative Targeted Oral Therapy
A 38-year-old man diagnosed with stage 4 head and neck cancer has successfully undergone treatment at Fortis Hospital, Manesar, using targeted oral therapy. The patient, who was initially diagnosed with a tumor in his throat, had been experiencing symptoms such as...
On World Kidney Cancer Day, physicians at Mohali’s Fortis Hospital launch an initiative to educate the public about the causes and symptoms of kidney cancer.
On June 19, World Kidney Cancer Day, doctors at Fortis Hospital in Mohali are raising awareness about the increasing incidence of kidney cancer in India. They are highlighting the symptoms of the disease, which include abdominal pain, swelling in the abdomen,...
Manipal and Fortis are engaging in discussions to secure Rs 5,000 crore for a potential acquisition of Sahyadri Hospitals.
The bidding process for Sahyadri Hospitals, a multispecialty hospital chain, is nearing its deadline of June 22. Interested bidders, including Manipal Health Enterprises and Fortis Healthcare, are in talks with foreign lenders to secure financing of up to Rs 5,000...
Fortis Healthcare launches state-of-the-art outpatient clinic for specialized care in Guwahati, as reported by Healthcare Asia Magazine
Fortis Healthcare, a leading integrated healthcare delivery service provider, has launched a super-speciality outpatient clinic in Guwahati, Assam. The clinic, which is the first of its kind in the region, aims to provide access to quality healthcare services to the...
Fortis Hospital Bannerghatta Road Successfully Treats 3-Year-Old Girl Suffering from Aggressive Blood Cancer Complicated by Life-Threatening Condition
A 3-year-old girl, Baby Ria, was successfully treated for Pre-B Acute Lymphoblastic Leukemia (ALL) at Fortis Hospital, Bannerghatta Road, Bengaluru. She was diagnosed with the aggressive form of blood cancer after presenting with high-grade fever, facial swelling, and...
Fortis Hospital Bannerghatta Road Successfully Treats 3-Year-Old Girl with Aggressive Blood Cancer Complicated by Life-Threatening Condition
A 3-year-old girl was successfully treated for an aggressive form of blood cancer at Fortis Hospital Bannerghatta Road. The child was diagnosed with Acute Lymphoblastic Leukemia (ALL), a type of cancer that affects the blood and bone marrow. The disease is...
Nomura elevates price target for Fortis Healthcare, retains ‘buy’ rating, reports Medical Buyer
Nomura, a research firm, has revised its price target for Fortis Healthcare from Rs 700 to Rs 820, while maintaining its "buy" rating. The firm attributes this increase to the company's strong growth prospects, driven by its existing infrastructure and strategic...
A 68-year-old woman undergoes successful Reverse Total Shoulder Replacement Surgery at Fortis Hospital Nagarbhavi
A 68-year-old woman, Mrs. Basanti, was successfully treated for severe shoulder arthritis at Fortis Hospital Nagarbhavi in Bangalore. She had been suffering from intense pain and limited mobility in her right shoulder for over two years, which affected her daily...